Serum YKL-40: a new independent prognostic marker for skeletal complications in patients with multiple myeloma

References

• Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78: 21–33.
   PubMed Web of Science ®Google Scholar
• Roodman GD. Pathogenesis of myeloma bone disease. Leukemia 2009;23:435–441.
   PubMed Web of Science ®Google Scholar
• Minter AR, Simpson H, Weiss BM, et al. Bone disease from monoclonal gammopathy of undetermined significance to multiple myeloma: pathogenesis, interventions, and future opportunities. Semin Hematol 2011;48:55–65.
   PubMed Web of Science ®Google Scholar
• Terpos E, Morgan G, Dimopoulos MA, et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol 2013;31:2347–2357.
   PubMed Web of Science ®Google Scholar
• Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 2004;9(Suppl. 4): 28–37.
   PubMed Web of Science ®Google Scholar
• Pozzi S, Raje N. The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future. Oncologist 2011;16: 651–662.
   PubMed Web of Science ®Google Scholar
• Terpos E, Efstathiou E, Christoulas D, et al. RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases. Expert Opin Biol Ther 2009;9:465–479.
   PubMed Web of Science ®Google Scholar
• Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29: 1125–1132.
   PubMed Web of Science ®Google Scholar
• Hageman K, Patel KC, Mace K, et al. The role of denosumab for prevention of skeletal-related complications in multiple myeloma. Ann Pharmacother 2013;47:1069–1074.
   PubMed Web of Science ®Google Scholar
• Fulciniti M, Tassone P, Hideshima T, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009;114:371–379.
   PubMed Web of Science ®Google Scholar
• Munshi NC, Beck JT, Bensinger W, et al. Early evidence of anabolic bone activity of BHQ880, a fully human anti-DKK1 neutralizing antibody: results of a phase 2 study in previously untreated patients with smoldering multiple myeloma at risk for progression. Blood 2012;120(Suppl. 1): Abstract 331.
   Google Scholar
• Roodman GD. Targeting the bone microenvironment in multiple myeloma. J Bone Miner Metab 2010;28:244–250.
   PubMed Web of Science ®Google Scholar
• Ciolli S. Effects on bone metabolism of new therapeutic strategies with standard chemotherapy and biologic drugs. Clin Cases Miner Bone Metab 2013;10:183–186.
   PubMedGoogle Scholar
• Mohty M, Malard F, Mohty B, et al. The effects of bortezomib on bone disease in patients with multiple myeloma. Cancer 2014; 120:618–623.
   PubMed Web of Science ®Google Scholar
• Terpos E, Christoulas D, Kastritis E, et al. The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group. Am J Hematol 2014;89:34–40.
   PubMed Web of Science ®Google Scholar
• Coleman R, Brown J, Terpos E, et al. Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev 2008;34:629–639.
   PubMed Web of Science ®Google Scholar
• Terpos E, Dimopoulos MA, Sezer O, et al. The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. Leukemia 2010;24: 1700–1712.
   PubMed Web of Science ®Google Scholar
• Terpos E, Berenson J, Cook RJ, et al. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Leukemia 2010;24:1043–1049.
   PubMed Web of Science ®Google Scholar
• Wu P, Walker BA, Brewer D, et al. A gene expression-based predictor for myeloma patients at high risk of developing bone disease on bisphosphonate treatment. Clin Cancer Res 2011;17: 6347–6355.
   PubMed Web of Science ®Google Scholar
• Johansen JS, Schultz NA, Jensen BV. Plasma YKL-40: a potential new cancer biomarker? Future Oncol 2009;5:1065–1082.
   PubMed Web of Science ®Google Scholar
• Lee CG, Da Silva CA, la Cruz CS, et al. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol 2011;73:479–501.
   PubMed Web of Science ®Google Scholar
• He CH, Lee CG, Dela Cruz CS, et al. Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor alpha2. Cell Rep 2013;4:830–841.
   PubMed Web of Science ®Google Scholar
• Francescone RA, Scully S, Faibish M, et al. Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J Biol Chem 2011;286:15332–15343.
   PubMed Web of Science ®Google Scholar
• Shao R, Francescone R, Ngernyuang N, et al. Anti-YKL-40 antibody and ionizing irradiation synergistically inhibit tumor vascularization and malignancy in glioblastoma. Carcinogenesis 2014;35:373–382.
   PubMed Web of Science ®Google Scholar
• Johansen JS, Hoyer PE, Larsen LA, et al. YKL-40 protein expression in the early developing human musculoskeletal system. J Histochem Cytochem 2007;55:1213–1228.
   PubMed Web of Science ®Google Scholar
• Ringsholt M, Hogdall EV, Johansen JS, et al. YKL-40 protein expression in normal adult human tissues--an immunohistochemical study. J Mol Histol 2007;38:33–43.
   PubMed Web of Science ®Google Scholar
• Di Rosa M, Tibullo D, Vecchio M, et al. Determination of chitinases family during osteoclastogenesis. Bone 2014;61:55–63.
   PubMed Web of Science ®Google Scholar
• Bigg HF, Wait R, Rowan AD, et al. The mammalian chitinase-like lectin, YKL-40, binds specifically to type I collagen and modulates the rate of type I collagen fibril formation. J Biol Chem 2006;281: 21082–21095.
   PubMed Web of Science ®Google Scholar
• Mylin AK, Rasmussen T, Johansen JS, et al. Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells. Eur J Haematol 2006;77:416–424.
   PubMed Web of Science ®Google Scholar
• Mylin AK, Abildgaard N, Johansen JS, et al. High serum YKL-40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patients. Eur J Haematol 2008;80: 310–317.
   PubMed Web of Science ®Google Scholar
• Mylin AK, Andersen NF, Johansen JS et al. Serum YKL-40 and bone marrow angiogenesis in multiple myeloma. Int J Cancer 2009;124:1492–1494.
   PubMed Web of Science ®Google Scholar
• Lenhoff S, Hjorth M, Westin J, et al. Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group. Br J Haematol 2006;133: 389–396.
   PubMed Web of Science ®Google Scholar
• Gimsing P, Carlson K, Turesson I, et al. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. Lancet Oncol 2010;11: 973–982.
   PubMed Web of Science ®Google Scholar
• Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247–254.
   PubMed Web of Science ®Google Scholar
• Johansen JS, Lottenburger T, Nielsen HJ, et al. Diurnal, weekly, and long-time variation in serum concentrations of YKL-40 in healthy subjects. Cancer Epidemiol Biomarkers Prev 2008;17: 2603–2608.
   PubMed Web of Science ®Google Scholar
• Johansen JS, Moller S, Price PA, et al. Plasma YKL-40: a new potential marker of fibrosis in patients with alcoholic cirrhosis? Scand J Gastroenterol 1997;32:582–590.
   PubMed Web of Science ®Google Scholar
• Watts NB. Clinical utility of biochemical markers of bone remodeling. Clin Chem 1999;45:1359–1368.
   PubMed Web of Science ®Google Scholar
• Bjarnason NH, Henriksen EE, Alexandersen P, et al. Mechanism of circadian variation in bone resorption. Bone 2002;30:307–313.
   PubMed Web of Science ®Google Scholar
• Hogdall EV, Johansen JS, Kjaer SK, et al. Stability of YKL-40 concentration in blood samples. Scand J Clin Lab Invest 2000;60: 247–251.
   PubMed Web of Science ®Google Scholar
• Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 1993;268:25803–25810.
   PubMed Web of Science ®Google Scholar
• Johansen JS, Williamson MK, Rice JS, et al. Identification of proteins secreted by human osteoblastic cells in culture. J Bone Miner Res 1992;7:501–512.
   PubMed Web of Science ®Google Scholar
• Connor JR, Dodds RA, Emery JG, et al. Human cartilage glycoprotein 39 (HC gp-39) mRNA expression in adult and fetal chondrocytes, osteoblasts and osteocytes by in-situ hybridization. Osteoarthritis Cartilage 2000;8:87–95.
   PubMed Web of Science ®Google Scholar
• Benz K, Breit S, Lukoschek M, et al. Molecular analysis of expansion, differentiation, and growth factor treatment of human chondrocytes identifies differentiation markers and growth-related genes. Biochem Biophys Res Commun 2002;293:284–292.
   PubMed Web of Science ®Google Scholar
• Volck B, Price PA, Johansen JS, et al. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians 1998;110:351–360.
   PubMedGoogle Scholar
• Krause SW, Rehli M, Kreutz M, et al. Differential screening identifies genetic markers of monocyte to macrophage maturation. J Leukoc Biol 1996;60:540–545.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick RB, Emery JG, Connor JR, et al. Induction and expression of human cartilage glycoprotein 39 in rheumatoid inflammatory and peripheral blood monocyte-derived macrophages. Exp Cell Res 1997;237:46–54.
   PubMed Web of Science ®Google Scholar
• Johansen JS, Jensen BV, Roslind A, et al. Is YKL-40 a new therapeutic target in cancer? Expert Opin Ther Targets 2007;11: 219–234.
   PubMed Web of Science ®Google Scholar
• Coffman FD. Chitinase 3-like-1 (CHI3L1): a putative disease marker at the interface of proteomics and glycomics. Crit Rev Clin Lab Sci 2008;45:531–562.
   PubMed Web of Science ®Google Scholar